Recent Advances in the Treatment of Advanced HER2+ Breast Cancer: SABCS 2024 - Episode 11
Emerging Frontline, Adjuvant, and Neoadjuvant Strategies with T-DXd in HER2+ Breast Cancer
Panelists discuss how emerging data from trials such as DESTINY-Breast09, which is evaluating first-line trastuzumab deruxtecan (T-DXd) with or without pertuzumab, could potentially reshape the treatment paradigm for HER2+ metastatic breast cancer (mBC) by establishing new standards for initial therapy and optimal combination approaches.
Video content above is prompted by the following:
Briefly comment on other novel strategies currently under investigation in HER2+ metastatic breast cancer and discuss their potential impact on future management in this patient population.
• Dr Hurvitz: DESTINY-Breast09 – 1L T-DXd ± pertuzumab in HER2+ mBC
Related Content:
